Incidence and clinical complications of myelodysplastic syndromes among United States Medicare beneficiaries

Journal of Clinical Oncology

Volumn 28, Issue 17, 2010, Pages 2847-2852

  Goldberg, Stuart L ^a   Chen, Er ^a   Corral, Mitra ^a   Guo, Amy ^a   Mody Patel, Nikita ^a   Pecora, Andrew L ^a   Laouri, Marianne ^a  

^a NONE

Author keywords

[No Author keywords available]

Indexed keywords

ACUTE GRANULOCYTIC LEUKEMIA; AGED; ARTICLE; CANCER CHEMOTHERAPY; CANCER MORTALITY; CANCER RADIOTHERAPY; CANCER SURVIVAL; COMORBIDITY; CONGESTIVE HEART FAILURE; DIABETES MELLITUS; DYSPNEA; ERYTHROCYTE TRANSFUSION; FEMALE; HEALTH CARE COST; HEART ARRHYTHMIA; HEART INFARCTION; HUMAN; INCIDENCE; INSURANCE; LIVER DISEASE; MAJOR CLINICAL STUDY; MALE; MEDICAL RECORD REVIEW; MEDICARE; MYELODYSPLASTIC SYNDROME; PRIORITY JOURNAL; SEPSIS; UNITED STATES; BLOOD TRANSFUSION; ECONOMICS; PATHOLOGY; RETROSPECTIVE STUDY; REVIEW; STATISTICS;

AGED; AGED, 80 AND OVER; BLOOD TRANSFUSION; FEMALE; HUMANS; MALE; MEDICARE; MYELODYSPLASTIC SYNDROMES; RETROSPECTIVE STUDIES; UNITED STATES;

EID: 77956397358     PISSN: 0732183X     EISSN: 15277755     Source Type: Journal    
DOI: 10.1200/JCO.2009.25.2395     Document Type: Article

References (22)

1. Cazzola M, Malcovati L: Myelodysplastic syndromes: Coping with ineffective hematopoiesis. N Engl J Med 352:536-538, 2005 (Pubitemid 40204666)
2. Nimer, SD: Myelodysplastic syndromes. Blood 111:4841-4851, 2008
3. Stone R, Sekeres M, Garcia-Manero G, et al: Recent advances in low- and intermediate-1-risk myelodysplastic syndrome: Developing a consensus for optimal therapy. Clin Adv Hematol Oncol 6:1-15, 2008
4. Kantarjian H, O'Brien S, Cortes J, et al: Therapeutic advances in leukemia and myelodysplastic syndrome over the past 40 years. Cancer 113:1933-1952, 2008 (supp 7)
5. Guralnik JM, Eisenstaedt RS, Ferrucci L, et al: Prevalence of anemia in persons 65 years and older in the United States: Evidence for a high rate of unexplained anemia. Blood 104:2263-2268, 2004 (Pubitemid 39331821)
6. Harris NL, Jaffe ES, Diebold J, et al: World Health Organization classification of neoplastic diseases of the hematopoietic and lymphoid tissues: Report of the Clinical Advisory Committee Meeting - Airlie House, Virginia, November 1997. J Clin Oncol 17:3835-3849, 1999
7. Ma X, Does M, Raza A, et al: Myelodysplastic syndromes: Incidence and survival in the United States. Cancer 109:1536-1542, 2007 (Pubitemid 46595689)
8. Rollison DE, Howlader N, Smith MT, et al: Epidemiology of myelodysplastic syndromes and chronic myeloproliferative disorders in the United States, 2001-2004, using data from the NAACCR and SEER programs. Blood 112:45-52, 2008
9. Malcovati L, Germing U, Kuendgen A, et al: Time-dependent prognostic scoring system for predicting survival and leukemic evolution in myelodysplastic syndromes. J Clin Oncol 25:3503-3510, 2007 (Pubitemid 47315575)
10. Sanz G, Nomdedeu B, Such E, et al: Independent impact of iron overload and transfusion dependency on survival and leukemic evolution in patients with myelodysplastic syndrome. Blood 112, 2008 (abstr 640)
11. Delea TE, Hagiwara M, Phatak PD: Retrospective study of the association between transfusion frequency and potential complications of iron overload in patients with myelodysplastic syndrome and other acquired hematopoietic disorders. Curr Med Res Opin 25:139-147, 2009
12. Fisher ES, Whaley FS, Krushat WM, et al: The accuracy of Medicare's hospital claims data: Progress has been made, but problems remain. Am J Public Health 82:243-248, 1992
13. Jollis JG, Ancukiewicz M, DeLong ER, et al: Discordance of databases designed for claims payment versus clinical information systems: Implications for outcomes research. Ann Intern Med 119:844-850, 1993 (Pubitemid 24012651)
14. Fritz A, Percy C, Jack A, et al: International Classification of Diseases for Oncology (ed 3). Geneva, Switzerland, World Health Organization, 2000
15. Strom SS, Vélez-Bravo V, Estey EH: Epidemiology of myelodysplastic syndromes. Semin Hematol 45:8-13, 2008
16. Germing U, Neukirchen J, Haas R: The epidemiology of myelodysplastic syndromes. Clinical Leukemia 2:34-38, 2008
17. Komrokji RS, Matacia-Murphy GM, Al Ali NH, et al: Outcome of patients with myelodysplastic syndromes in the Veterans Administration population. Leuk Res 34:59-62, 2010
18. Brechignac S, Hellstrom-Lindberg E, Bowen DT, et al: Quality of life and economic impact of red blood cell transfusions on patients with myelodysplastic syndromes. Blood 104:236b, 2004 (abstr 4716)
19. Sekeres MA, Schoonen WM, Kantarjian H, et al: Characteristics of US patients with myelodysplastic syndromes: Results of six cross-sectional physician surveys. J Natl Cancer Inst 100:1542-1551, 2008
20. Malcovati L, Della Porta M, Pascutto C, et al: Prognostic factors and life expectancy in myelodysplastic syndromes classified according to WHO criteria. J Clin Oncol 23:7594-7603, 2005
21. Rose C, Brechignac S, Vassilief D, et al: Positive impact of iron chelation therapy on survival in regularly transfused MDS patients: A prospective analysis by the GFM. Blood 110, 2007 (abstr 249)
22. Leitch HA, Leger CS, Goodman TA, et al: Improved survival in patients with m myelodysplastic syndrome receiving iron chelation therapy. Clinical Leukemia 2:205-211, 2008